Trial Profile
A Randomized, Open-label, 4-period Crossover Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD) and the PK/PD Relationship of DPOC-4088 After Single Oral Dosing of 100 and 200 mg in 2 Prolonged Release Formulations (16 and 20 hr) in 12 Healthy Young Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Dec 2011
Price :
$35
*
At a glance
- Drugs DP 4088 (Primary)
- Indications Deep vein thrombosis
- Focus Pharmacokinetics
- 13 Dec 2011 Results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
- 06 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 May 2011 New trial record